You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Patent: 9,949,971


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,949,971
Title:Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
Abstract: Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton\'s tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the .gamma.- and .delta.-isoforms and selective for both .gamma.- and .delta.-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-.delta. inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-.delta. inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.
Inventor(s): Hamdy; Ahmed (Santa Cruz, CA), Rothbaum; Wayne (Delray Beach, FL), Izumi; Raquel (San Carlos, CA), Lannutti; Brian (Solana Beach, CA), Covey; Todd (San Carlos, CA), Ulrich; Roger (Sammamish, WA), Johnson; Dave (Aptos, CA), Barf; Tjeerd (Ravenstein, NL), Kaptein; Allard (Zaltbommel, NL)
Assignee: Acerta Pharma B.V. (Oss, NL)
Application Number:15/319,740
Patent Claims:see list of patent claims

Details for Patent 9,949,971

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2034-06-17
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 10/26/2009 ⤷  Try a Trial 2034-06-17
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 04/01/2011 ⤷  Try a Trial 2034-06-17
Novartis Pharmaceuticals Corporation KESIMPTA ofatumumab Injection 125326 08/20/2020 ⤷  Try a Trial 2034-06-17
Genentech, Inc. GAZYVA obinutuzumab Injection 125486 11/01/2013 ⤷  Try a Trial 2034-06-17
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2034-06-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.